Demographic and histologic characteristics
| Cohort | Pre-OPBS (n = 12) | Post-OPBS (n = 20) | p value |
|---|---|---|---|
| Age, mean (range), yr | 65.2 (57–78) | 66.7 (37–84) | 0.70 |
| CCI, mean (range) | 1.08 (0–2) | 1.90 (0–3) | 0.024 |
| Histology, no. (%) | 0.52 | ||
| Invasive ductal carcinoma | 6 (50.0) | 14 (70.0) | |
| Mixed ductal and lobular carcinoma | 1 (8.3) | 1 (5.0) | |
| DCIS | 5 (41.7) | 5 (25.0) | |
| Receptor status, no. (%) | 0.53 | ||
| ER/PR positive | 10 (83.3) | 15 (75.0) | |
| HER-2 positive | 0 (0) | 4 (20.0) | |
| Triple negative | 1 (8.3) | 1 (5.0) | |
| Unknown | 1 (8.3) | 3 (15.0) | |
| Nodal status, no. (%) | > 0.99 | ||
| Negative | 11 (91.6) | 18 (90.0) | |
| Positive | 1 (8.3) | 2 (10.0) | |
| Pathologic stage, no. (%) | 0.70 | ||
| pTis | 4 (33.3) | 5 (25.0) | |
| pT1 | 5 (41.7) | 12 (60.0) | |
| pT2 | 3 (25.0) | 3 (15.0) | |
| Overall stage, no. (%) | 0.91 | ||
| 0 | 4 (33.3) | 5 (25.0) | |
| IA | 5 (41.7) | 9 (45.0) | |
| IB | 0 (0) | 1 (5.0) | |
| IIA | 2 (16.7) | 4 (20.0) | |
| IIB | 1 (8.3) | 0 (0) | |
| IIIA | 0 (0) | 1 (5.0) |
CCI = Charlson Comorbidity Index; DCIS = ductal carcinoma in situ; ER = estrogen receptor; HER2 = human epidermal growth factor receptor 2; OPBS = oncoplastic breast surgery; PR = progesterone receptor.